Skip to content

The Purpose of This Study is to Look at Pelvic Support Problems, Also Commonly Known as Pelvic Organ Prolapse

FemmeJock: A Pilot Study to Assess Patient Satisfaction and Improvement of Pelvic Floor Symptoms Using a Pelvic Floor Support Girdle in Women With Uterovaginal Prolapse.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00964197
Enrollment
100
Registered
2009-08-24
Start date
2008-11-01
Completion date
2014-04-01
Last updated
2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

FemmeJock, Pelvic Organ Prolapse

Brief summary

FemmeJock is a pelvic floor support system developed by pelvic floor physiotherapists for patients with pelvic organ prolapse in order to ameliorate symptoms of pelvic floor pressure and discomfort. The device is a girdle to be worn on the outside of underwear. The device is machine washable and there are no documented risks with wearing it. This product is currently being used by pelvic floor physiotherapists and has been subjectively reported by individual accounts as being successful in improving pelvic floor symptoms. The efficacy of this product has not been previously studied in women with pelvic organ prolapse. The investigators are proposing a pilot study with the following specific aims: 1. to assess patient satisfaction and continuation of use of the FemmeJock support system after 3 months of treatment. 2. to describe, if any, the reasons for discontinuation associated with the use of this product, and 3. to assess whether women experience improvement of pelvic floor symptoms after using this product.

Detailed description

This will be a prospective pilot study in order to determine the efficacy and tolerability of FemmeJock in patients with pelvic organ prolapse. We plan to enroll 30 patients who will be recruited from the OU Health Science Center. We will offer study participation to patients who meet the inclusion criteria listed below, and who are: (1) awaiting surgical management and desire a temporary nonsurgical option, (2) seeking permanent nonsurgical treatment, or (3) who have a contraindication to surgical management.

Interventions

DEVICEFemmeJock

The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* Pelvic organ prolapse, \> stage II * 1 or more prolapse associated symptoms: * Herniation symptoms * Pelvic pressure * Bulging tissue * Sexual dysfunction * Patient willingness to enroll * Available for 3 months of follow-up

Exclusion criteria

* Pregnancy or planning pregnancy within the next 3 months * Perineal ulcers or trauma * Anticipating relocation in next 3 months * Current pessary use * Dementia or inability to complete questionnaires * Chronic inflammatory or infectious vulvar condition (i.e., dermatologic conditions: lichen sclerosis or lichen planus, or vulvar candidiasis)

Design outcomes

Primary

MeasureTime frame
to assess patient satisfaction and continuation of use of the FemmeJock support system after 3 months of treatment.2 years

Secondary

MeasureTime frame
To describe, if any, the reasons for discontinuation associated with the use of this product.2 years
To assess whether women experience improvement of pelvic floor symptoms after using this product.2 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLieschen H. Quiroz, M.D.

University of Oklahoma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026